Semaglutide nausea symptom guide

Semaglutide nausea: current Wegovy rates and warning signs

Review nausea during semaglutide care using current Wegovy labeling, including injection trial rates, oral and injection route differences, vomiting and dehydration questions, product identity, and urgent warning signs.

Educational guideUpdated August 3, 2026

A label-first response to nausea during semaglutide care

Identify the exact product and route: Wegovy injection or tablets, Ozempic injection or tablets, or a patient-specific compounded semaglutide prescription.

Describe nausea separately from vomiting, reflux, early fullness, bloating, constipation, diarrhea, and severe or persistent abdominal pain.

Record onset, severity, recurrence, food and fluid intake, urine output, and timing relative to treatment, a clinician-directed change, refill, illness, or another medicine.

Contact the prescriber before changing treatment or adding an anti-nausea product; follow individualized food, fluid, glucose, and medication instructions.

Use urgent in-person care for severe abdominal, dehydration, bleeding, allergic, neurologic, or other emergency warning signs.

Direct answer

Nausea is a common adverse reaction with semaglutide, but rates are product- and study-specific. In pooled adult weight-management trials in the current Wegovy label, nausea occurred in 44% of participants receiving the 2.4 mg once-weekly injection versus 16% receiving placebo. That comparison does not prove semaglutide caused every episode and should not be transferred to Ozempic, oral Wegovy, or a patient-specific compounded prescription. Contact the prescriber for new, persistent, severe, recurrent, or intake-limiting nausea, especially with vomiting, diarrhea, constipation, reduced urination, dizziness, a clinician-directed treatment change, or another glucose-lowering medicine. Severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, fainting, confusion, jaundice, trouble breathing, facial or throat swelling, or blood in vomit needs prompt in-person assessment.

Current label answer

Wegovy injection trials report nausea in 44% versus 16% with placebo

The Wegovy prescribing information updated June 18, 2026 covers both subcutaneous injection and once-daily tablets. In pooled adult weight-management trials of the 2.4 mg once-weekly injection, nausea was reported in 44% of Wegovy-treated participants and 16% of placebo participants. Nausea led to permanent discontinuation in 1.8% of Wegovy-treated participants versus 0.2% receiving placebo. These figures establish a recognized association in the studied population, but they do not identify the cause, expected severity, or duration of one person’s symptoms.

Keep the 44% versus 16% comparison tied to pooled adult trials of branded Wegovy 2.4 mg weekly injection.
The current label says common adverse-reaction types and frequency with Wegovy 25 mg tablets were similar to those in the injection table, but it does not publish a tablet-specific nausea percentage in that table.
Do not apply the injection rate to Ozempic, a different indication or strength, oral Wegovy, or compounded semaglutide without product-specific evidence.

Symptom pattern

Nausea, vomiting, reflux, and severe abdominal pain are not interchangeable

“Nausea” usually means queasiness or feeling as though vomiting may occur. It should be recorded separately from actual vomiting, heartburn or reflux, early fullness, bloating, constipation, diarrhea, pain, fever, or jaundice. A useful review explains when symptoms begin, how long they last, whether they recur, what can be eaten or drunk, and whether normal activity is affected. Timing after treatment can support a medication review without proving that semaglutide is the only cause.

Record the number of vomiting or diarrhea episodes, the ability to keep fluids down, urine amount and color, dizziness, fainting, weakness, and recent weight or intake changes.
Report severe or persistent abdominal pain, pain spreading to the back, right-upper-abdominal pain, fever, yellow skin or eyes, pale stools, dark urine, abdominal swelling, or inability to pass stool or gas.
Do not assume every stomach symptom is an expected adjustment; infection, pregnancy, migraine, gallbladder or pancreatic disease, obstruction, gastroparesis, reflux, another medicine, or another condition may require different care.

Hydration, intake, and glucose

Vomiting or poor intake can change the urgency of nausea

Current Wegovy labeling warns about acute kidney injury from volume depletion and notes that most reported events occurred in people who experienced gastrointestinal reactions leading to dehydration. It also warns that hypoglycemia risk can increase when semaglutide is used with insulin or an insulin secretagogue such as a sulfonylurea. Nausea alone does not diagnose dehydration, kidney injury, or low blood sugar, so the prescriber needs the full symptom, intake, medication, and monitoring pattern.

Share food and fluid intake, vomiting, diarrhea, constipation, urine output, dizziness, fainting, heat exposure, kidney history, recent illness, and blood-pressure or diuretic medicines.
If glucose monitoring is part of care, record readings with symptoms, meals, activity, alcohol, insulin, sulfonylureas, and other glucose-lowering medicines; follow the individualized response plan.
Do not improvise a medicine hold, extra or catch-up dose, electrolyte recipe, anti-nausea medicine, laxative, supplement, or glucose treatment from a forum post.

Product and treatment review

The exact semaglutide product matters before the next decision

Wegovy and Ozempic are FDA-approved finished semaglutide products with product-specific indications, routes, presentations, instructions, and evidence. A patient-specific compounded semaglutide preparation is not an FDA-approved finished drug product and may differ in concentration, inactive ingredients, container, labeling, storage, and beyond-use date. Nausea after a refill or product change should prompt verification of the current label and pharmacy rather than an assumption that every pen, tablet, or vial is interchangeable.

Bring the product name, indication, route, strength or concentration, manufacturer or dispensing pharmacy, prescriber, refill or lot details, storage history, and a photo of the current label.
Contact the responsible prescriber before skipping, repeating, stopping, restarting, splitting, increasing, decreasing, or converting between a tablet and injection.
Avoid research-use products, unlabeled vials, counterfeit pens or tablets, copied syringe charts, and sellers that provide semaglutide without prescription-first clinician review.

Escalation

Persistent nausea and emergency warning signs need different pathways

Mild nausea with preserved food and fluid intake is different from repeated vomiting, severe pain, dehydration, bleeding, serious allergy symptoms, or neurologic change. The prescribing clinician can review a non-emergency pattern and decide whether examination, testing, monitoring, or a treatment change is appropriate. Urgent warning signs should not wait for a portal reply or the next refill visit.

Contact the prescriber for new, persistent, worsening, recurrent, or function-limiting nausea; vomiting; poor intake; markedly reduced urination; dizziness; symptoms after a refill or clinician-directed change; or uncertainty before the next treatment.
Seek prompt in-person assessment for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, fainting, confusion, severe weakness, jaundice, blood or coffee-ground material in vomit, black stools, chest pain, or trouble breathing.
Facial or throat swelling, widespread hives with breathing difficulty, collapse, or another serious allergic pattern needs emergency evaluation.

Patient safety checklist

Questions to ask about nausea during semaglutide treatment

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Which exact product and route am I using: Wegovy injection or tablets, Ozempic injection or tablets, or a patient-specific compounded semaglutide prescription?

✓

When did nausea begin, how long does it last, how severe is it, and did it follow treatment, a clinician-directed change, refill, illness, travel, or another medicine?

✓

Can I keep fluids and food down, how much am I drinking, how often am I urinating, and do I have vomiting, diarrhea, constipation, reflux, dizziness, or fainting?

✓

Do I have severe or persistent abdominal pain, pain spreading to the back, fever, jaundice, abdominal swelling, blood in vomit, black stools, rash, or swelling?

✓

Do insulin, sulfonylureas, SGLT2 inhibitors, metformin, diuretics, blood-pressure medicines, pain medicines, antibiotics, alcohol, cannabis, vitamins, or supplements change the review?

✓

If glucose or blood-pressure monitoring is part of care, which readings and symptoms should trigger same-day guidance or urgent assessment?

✓

Should the current product label, pharmacy, refill or lot, storage history, concentration, route, or inactive ingredients be reviewed before the next treatment decision?

✓

Who should I contact before the next treatment or refill, and which symptoms should bypass messaging for urgent or emergency care?

FAQs

Short answers for patients

How common is nausea with semaglutide?

The most useful rate is product- and study-specific. In pooled adult weight-management trials of branded Wegovy 2.4 mg weekly injection, nausea occurred in 44% of treated participants versus 16% receiving placebo. That comparison is not a universal rate for every semaglutide product, route, strength, or patient.

How long does semaglutide nausea last?

The current Wegovy label does not provide one nausea duration that applies to every patient. Record onset, severity, recurrence, exact product and route, intake, vomiting or diarrhea, urine output, treatment or refill timing, and other medicines. Contact the prescriber for persistent, severe, recurrent, worsening, or intake-limiting symptoms.

Does the Wegovy injection nausea rate apply to oral Wegovy?

Not as a tablet-specific percentage. The current label says the types and frequency of common adverse reactions in the Wegovy 25 mg tablet trial were similar to those listed in the injection table, but it does not publish a tablet-specific nausea rate there. Route- and product-specific instructions still matter.

Does the Wegovy nausea rate apply to compounded semaglutide?

No. A patient-specific compounded preparation is not an FDA-approved finished drug product and may differ in concentration, inactive ingredients, presentation, labeling, storage, and beyond-use date. Wegovy injection trial rates do not establish a nausea incidence or product quality for a compounded preparation.

Should I skip semaglutide if I feel nauseated?

Do not skip, repeat, stop, restart, split, or change a semaglutide prescription based on generic online advice. Contact the responsible prescriber with the symptom pattern and product details before the next treatment decision. Urgent warning signs require in-person assessment.

Can I take an anti-nausea medicine with semaglutide?

Ask the responsible clinician or pharmacist before adding an anti-nausea medicine. The cause of nausea, pregnancy possibility, heart-rhythm risk, sedation, constipation, other medicines, and the exact semaglutide product can affect whether a proposed treatment is appropriate.

When is nausea during semaglutide care urgent?

Seek prompt in-person care for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, fainting, confusion, markedly reduced urination, severe weakness, jaundice, blood or coffee-ground material in vomit, black stools, trouble breathing, facial or throat swelling, or another serious allergic pattern.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Current WEGOVY prescribing information — updated June 18, 2026 MedlinePlus: Semaglutide injection drug information — revised May 15, 2026 MedlinePlus: Nausea and vomiting MedlinePlus: Dehydration FDA: Compounding and the FDA — Questions and Answers FDA MedWatch: Report a serious problem with a medical product Peptide12: Compounded semaglutide injection Peptide12: Wegovy Peptide12: Ozempic Peptide12: GLP-1 nausea and vomiting Peptide12: Semaglutide headache Peptide12: Semaglutide fatigue Peptide12: GLP-1 kidney and dehydration risk Peptide12: When to message your clinician Peptide12: How online peptide therapy works